38 Jean Paul Clozel Photos and Premium High Res Pictures - Getty Images
J&J Makes Big Bet on Rare Disease With $30 Billion Actelion Deal - Bloomberg
Actelion spinout Idorsia hits goals in insomnia phase 2, sparking stock rise and talk of partnering up for pivotal trial | Fierce Biotech
Idorsia Pharmaceuticals Ltd - Our CEO, Jean-Paul Clozel closed out the year with the remark: We advanced each of our clinical programs, with the first Phase 3 results expected soon. Since the
Thomas Clozel, from medicine to predictive algorithms - News in France
Startup Guide - Jean-Paul and Martine Clozel are... | Facebook
Actelion: Die Knackpunkte eines Deals mit Johnson & Johnson | Tages-Anzeiger
Jean-Paul Clozel
Actelion's Jean-Paul Clozel aims to keep group's independence | Financial Times
Was plant das Ehepaar Clozel? | NZZ
Actelion-Verkauf - Jean-Paul und Martine Clozel: Das 30-Milliarden-Paar
Johnson & Johnson Chief Scientific Officer Pharmaceuticals Paul Stoffels (C) and Actelion CEO and founder Jean-Paul Clozel (R) attend a news conference at Actelion headquarters in Allschwil, Switzerland January 26, 2017. REUTERS/Arnd
Johnson & Johnson Chief Scientific Officer Pharmaceuticals Paul Stoffels (L) and Actelion CEO and founder Jean-Paul Clozel attend a news conference at Actelion headquarters in Allschwil, Switzerland January 26, 2017. REUTERS/Arnd Wiegmann
Jean-Paul Clozel | Financial Times
Jean-Paul und Martine Clozel - Ein Unternehmerpaar der besonderen Art - News - SRF
J&J seals $30bn Swiss Actelion deal | The Peninsula Qatar
Jean-Paul Clozel, un inconnu dans le top 100 des patrons
Idorsia's rival to Merck's insomnia drug clears phase 3 test | Fierce Biotech
Ernst and Young's world Entrepreneur Dr Jean Paul Clozel | Flickr
Les secrets de management de Jean-Paul Clozel, l'homme qui a vendu sa biotech 30 milliards - Challenges
